Filing Details

Accession Number:
0001062993-23-007221
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-17 18:37:22
Reporting Period:
2023-03-15
Accepted Time:
2023-03-17 18:37:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1177648 Enanta Pharmaceuticals Inc ENTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1571212 Sun Yat Or C/O Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown MA 02472
Sr. Vp & Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-15 13,925 $14.00 388,627 No 4 M Direct
Common Stock Disposition 2023-03-15 269 $43.92 388,358 No 4 S Direct
Common Stock Disposition 2023-03-15 13,656 $44.46 374,702 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-03-15 13,925 $0.00 13,925 $14.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-03-21 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2022.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.86 to $43.96, inclusive.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive.
  4. On March 21, 2013, the reporting person was granted an option to purchase 41,763 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.